surgoncoКреативная хирургия и онкологияCreative surgery and oncology2076-30932307-0501Башкирский государственный медицинский университет10.24060/2076-3093-2023-13-2-143-150surgonco-811Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWSОбзор низкомолекулярных противоопухолевых NF-κB-ингибиторовReview of Small Molecule Anticancer NF-κB Inhibitorshttps://orcid.org/0000-0001-9721-108XКзыргалинШ. Р.KzyrgalinSh. R.

Шамиль Римович Кзыргалин, к. м. н., доцент

ИДПО

кафедра онкологии с курсами онкологии и патологическойанатомии

Республика Башкортостан

Уфа

Shamil R. Kzyrgalin, Cand. Sci. (Med.), Assoc. Prof.

Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education

Ufa

ufa.shamil@gmail.comЯмидановР. С.YamidanovR. S.

Ренат Салекович Ямиданов, к. б. н.

ИДПО

кафедра онкологии с курсами онкологии и патологической анатомии

Республика Башкортостан

Уфа

Renat S. Yamidanov, Cand. Sci. (Biology)

Department of Oncology with Courses of Oncology and PathologicalAnatomy for Advanced Professional Education

Ufa

https://orcid.org/0000-0001-6745-219XНазмиеваК. А.NazmievaK. A.

Ксения Александровна Назмиева

ИДПО

кафедра урологии с курсом онкологии

Республика Башкортостан

Уфа

Ksenia A. Nazmieva, Department of Urology with a Course of Oncology forAdvanced Professional Education

Ufa

https://orcid.org/0000-0003-2047-963XГанцевШ. Х.GantsevSh. Kh.

Шамиль Ханафиевич Ганцев,  д. м. н., профессор

ИДПО

кафедра онкологии с курсами онкологии и патологическойанатомии

Республика Башкортостан

Уфа

Shamil Kh. Gantsev, Dr. Sci. (Med), Prof.

Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education

Ufa

Башкирский государственный медицинский университетРоссияBashkir State Medical UniversityRussian Federation202330062023132143150Copyright © Кзыргалин Ш.Р., Ямиданов Р.С., Назмиева К.А., Ганцев Ш.Х., 20232023Кзыргалин Ш.Р., Ямиданов Р.С., Назмиева К.А., Ганцев Ш.Х.Kzyrgalin S.R., Yamidanov R.S., Nazmieva K.A., Gantsev S.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgonco.ru/jour/article/view/811

   Онкологические заболевания являются одними из самых распространенных заболеваний в мире. Транскрипционный фактор NF-κB играет ключевою роль в различных физиологических процессах, таких как иммунный ответ, клеточная пролиферация, клеточный апоптоз и воспаление. Участие сигнальных путей, регулируемых NF-κB, в канцерогенезе, ангиогенезе, в том числе и в устойчивости опухолей к химио- и радиотерапии, делает его одной из идеальных мишеней направленного фармакологического воздействия при терапии рака. В статье представлен анализ литературы баз данных РИНЦ, PubMed, Scopus, Web of Science, Chemical Absracts NCCN, а также другие данные открытого доступа. Среди найденных NF-κB-ингибиторов были отобраны те, что регулируют процессы канцерогенеза. Аналитический интерес составили ингибиторы с противоопухолевым действием: ингибиторы тирозинкиназы Брутона (BTK), клеточные ингибиторы белков апоптоза (c-IAP), ингибиторы протеасом и один ингибитор транслокации NF-κB в ядро. Проанализированные нами препараты находятся на разных этапах разработки, они в той или иной степени продемонстрировали свою противоопухолевую активность. NF-κB-ингибиторы являются перспективными кандидатами в лекарственные средства, но так как NF-κB вовлечен в большинство биологических процессов, а широкий спектр действия может обуславливать побочные явления, то встает вопрос о селективном действии этих соединений.

   Cancer is one of the most common diseases in the world. Th e transcription factor NF-κB plays a key role in various physiological processes including immune response, cell proliferation, cell apoptosis and inflammation. Due to participation of NF-kappa B signaling pathways in carcinogenesis, angiogenesis, and tumor resistance to chemo- and radiotherapy, the factor is considered to be the ideal target for pharmacological treatment of cancer. Th e paper presents a literature review of the RSCI, PubMed, Scopus, Web of Science, Chemical Abstracts NCCN databases and other open access data. The carcinogenesis inhibitors were selected from all NF-κB inhibitors found. Inhibitors with antitumor activity of analytical interest include Bruton tyrosine kinase (BTK) inhibitors, cellular inhibitors of apoptosis proteins (c-IAP), proteasome inhibitors, and one inhibitor of NF-κB translocation to the nucleus. Th e authors analyzed products of diff erent development stages with recorded antitumor activity to varying degrees. NF-κB inhibitors are promising drug candidates, but since NF-κB is involved in most biological processes and the broad spectrum of action can cause side eff ects, the selective action of these compounds is to be explored.

ингибитор NF-κBканцерогенезагаммаглобулинемиятирозинкиназаингибиторы белков апоптозапротеасом ингибиторылимфомамиеломарак яичниковNF-κB inhibitorcarcinogenesisagammaglobulinemia tyrosine kinaseinhibitor of apoptosis proteinsproteasome inhibitorslymphomamyelomaovarian cancerДанная работа не финансироваласьThis work is not fundedReferencesSun S. C. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol. 2017; 17 (9): 545–58. DOI: 10.1038/nri.2017.52Sun S. C. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol. 2017; 17 (9): 545–58. DOI: 10.1038/nri.2017.52Mulero M. C., Huxford T., Ghosh G. NF-κB, IκB, and IKK: integral components of immune system signaling. Adv Exp Med Biol. 2019; 1172: 207–26. DOI: 10.1007/978-981-13-9367-9_10Mulero M. C., Huxford T., Ghosh G. NF-κB, IκB, and IKK: integral components of immune system signaling. Adv Exp Med Biol. 2019; 1172: 207–26. DOI: 10.1007/978-981-13-9367-9_10Taniguchi K., Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018; 18 (5): 309–24. DOI: 10.1038/nri.2017.142Taniguchi K., Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018; 18 (5): 309–24. DOI: 10.1038/nri.2017.142Oeckinghaus A., Hayden M. S., Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol. 2011; 12 (8): 695–708. DOI: 10.1038/ni.2065Oeckinghaus A., Hayden M. S., Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol. 2011; 12 (8): 695–708. DOI: 10.1038/ni.2065Yang C., Ran Q., Zhou Y., Liu S., Zhao C., Yu X., et al. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis. Apoptosis. 2020; 25 (5–6): 441–55. DOI: 10.1007/s10495-020-01604-6Yang C., Ran Q., Zhou Y., Liu S., Zhao C., Yu X., et al. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis. Apoptosis. 2020; 25 (5–6): 441–55. DOI: 10.1007/s10495-020-01604-6Feltham R., Vince J. E., Lawlor K. E. Caspase-8: Not so silently deadly. Clin Transl Immunol. 2017; 6 (1): e124. DOI: 10.1038/cti.2016.83Feltham R., Vince J. E., Lawlor K. E. Caspase-8: Not so silently deadly. Clin Transl Immunol. 2017; 6 (1): e124. DOI: 10.1038/cti.2016.83Manning B. D., Toker A. AKT/PKB signaling: navigating the network. Cell. 2017; 169 (3): 381–405. DOI: 10.1016/j.cell.2017.04.001Manning B. D., Toker A. AKT/PKB signaling: navigating the network. Cell. 2017; 169 (3): 381–405. DOI: 10.1016/j.cell.2017.04.001Gasser J. A., Inuzuka H., Wei W. Turning off AKT: PDPK1-dependent and-independent mechanisms. J Mol Cell Biol. 2017; 9 (5): 383–5.Gasser J. A., Inuzuka H., Wei W. Turning off AKT: PDPK1-dependent and-independent mechanisms. J Mol Cell Biol. 2017; 9 (5): 383–5.Ueki K., Fruman D. A. AKT/PKB signaling: a key player in insulin signaling, diabetes, and cancer. J Mol Cell Biol. 2017; 9 (5): 387–96.Ueki K., Fruman D. A. AKT/PKB signaling: a key player in insulin signaling, diabetes, and cancer. J Mol Cell Biol. 2017; 9 (5): 387–96.Bhujbal S. P., He W., Hah J. M. Design of novel IRAK4 inhibitors using molecular docking, dynamics simulation and 3D-QSAR studies. Molecules. 2022; 27 (19): 6307. DOI: 10.3390/molecules27196307Bhujbal S. P., He W., Hah J. M. Design of novel IRAK4 inhibitors using molecular docking, dynamics simulation and 3D-QSAR studies. Molecules. 2022; 27 (19): 6307. DOI: 10.3390/molecules27196307Su L. C., Xu W. D., Huang A. F. IRAK family in infl ammatory autoimmune diseases. Autoimmun Rev. 2020; 19 (3): 102461. DOI: 10.1016/j.autrev.2020.102461Su L. C., Xu W. D., Huang A. F. IRAK family in infl ammatory autoimmune diseases. Autoimmun Rev. 2020; 19 (3): 102461. DOI: 10.1016/j.autrev.2020.102461Coffey G., Betz A., De Guzman F., Pak Y., Inagaki M., Baker D. C., et al. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. J Pharmacol Exp Ther. 2014; 351 (3): 538–48. DOI: 10.1124/jpet.114.218164Coffey G., Betz A., De Guzman F., Pak Y., Inagaki M., Baker D. C., et al. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. J Pharmacol Exp Ther. 2014; 351 (3): 538–48. DOI: 10.1124/jpet.114.218164Yerlikaya A., Kanbur E. The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells. Curr Drug Targets. 2020; 21 (13): 1313–25. DOI: 10.2174/1389450121666200525004714Yerlikaya A., Kanbur E. The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells. Curr Drug Targets. 2020; 21 (13): 1313–25. DOI: 10.2174/1389450121666200525004714Капитонова М. А., Шадрина О. А., Королев С. П., Готтих М. Б. Основные подходы к контролируемой деградации белков в клетке. Молекулярная биология. 2021; 55 (4): 543–61. DOI: 10.31857/S0026898421040066Kapitonova M. A., Shadrina O. A., Korolev S. P., Gottikh M. B. Main approaches to controlled protein degradation in the cell. Molecular Biology. 2021; 55 (4): 543–61 (In Russ.). DOI: 10.31857/S0026898421040066Altun M., Galardy P. J. Shining a light on deubiquitinating enzymes: rapid development of inhibitors and activity-based probes. Curr Opin Chem Biol. 2009; 13 (5–6): 64–71. DOI: 10.1016/j.cbpa.2009.07.025Altun M., Galardy P. J. Shining a light on deubiquitinating enzymes: rapid development of inhibitors and activity-based probes. Curr Opin Chem Biol. 2009; 13 (5–6): 64–71. DOI: 10.1016/j.cbpa.2009.07.025Harrigan J. A., Jacq X., Martin N. M., Jackson S. P. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018; 17 (6): 57–78.Harrigan J. A., Jacq X., Martin N. M., Jackson S. P. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018; 17 (6): 57–78.Soucy T. A., Smith P. G., Milhollen M. A., Berger A. J., Gavin J. M., Adhikari S., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009; 458 (7239): 732–6.Soucy T. A., Smith P. G., Milhollen M. A., Berger A. J., Gavin J. M., Adhikari S., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009; 458 (7239): 732–6.Yu Q., Jiang Y., Sun Y. Anticancer drug discovery by targeting cullin neddylation. Acta Pharm Sin B. 2020; 10 (5): 746–65. DOI: 10.1016/j.apsb.2019.09.005Yu Q., Jiang Y., Sun Y. Anticancer drug discovery by targeting cullin neddylation. Acta Pharm Sin B. 2020; 10 (5): 746–65. DOI: 10.1016/j.apsb.2019.09.005Kudo N., Matsumori N., Taoka H., Fujiwara D., Schreiner E. P., Wolff B., et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modifi cation at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA. 1999; 96 (14): 9112–7. DOI: 10.1073/pnas.96.16.9112Kudo N., Matsumori N., Taoka H., Fujiwara D., Schreiner E. P., Wolff B., et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modifi cation at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA. 1999; 96 (14): 9112–7. DOI: 10.1073/pnas.96.16.9112Fung H. Y., Fu S. C., Chook Y. M. Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals. Elife. 2017; 6: e23961. DOI: 10.7554/eLife.23961Fung H. Y., Fu S. C., Chook Y. M. Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals. Elife. 2017; 6: e23961. DOI: 10.7554/eLife.23961Fu S. C., Fung H. Y. J., Cağatay T., Baumhardt J., Chook Y. M. Correlation of CRM1-NES affinity with nuclear export activity. Mol Biol Cell. 2018; 29 (17): 2037–44. DOI: 10.1091/mbc.E18-02-0096Fu S. C., Fung H. Y. J., Cağatay T., Baumhardt J., Chook Y. M. Correlation of CRM1-NES affinity with nuclear export activity. Mol Biol Cell. 2018; 29 (17): 2037–44. DOI: 10.1091/mbc.E18-02-0096Brown J. R., Robak T., Ghia P., Kahl B. S., Walker P., Janowski W., et al. Efficacy and safety of Zanubrutinib in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): follow-up results from arm C of the SEQUOIA (BGB-3111-304) Trial. Blood. 2020; 136 (Suppl 1): 11–2. DOI: 10.1182/blood-2020-134280Brown J. R., Robak T., Ghia P., Kahl B. S., Walker P., Janowski W., et al. Efficacy and safety of Zanubrutinib in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): follow-up results from arm C of the SEQUOIA (BGB-3111-304) Trial. Blood. 2020; 136 (Suppl 1): 11–2. DOI: 10.1182/blood-2020-134280Tam C. S., Opat S., D’Sa S., Jurczak W., Lee H. P., Cull G., et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020; 136 (18): 2038–50. DOI: 10.1182/blood.2020006844Tam C. S., Opat S., D’Sa S., Jurczak W., Lee H. P., Cull G., et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020; 136 (18): 2038–50. DOI: 10.1182/blood.2020006844Wang M., Rule S., Zinzani P. L., Goy A., Casasnovas O., Smith S. D., et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018; 391 (10121): 659–67. DOI: 10.1016/S0140-6736(17)33108-2Wang M., Rule S., Zinzani P. L., Goy A., Casasnovas O., Smith S. D., et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018; 391 (10121): 659–67. DOI: 10.1016/S0140-6736(17)33108-2Ghia P., Pluta A., Wach M., Lysak D., Kozak T., Simkovic M. et al. Acalabrutinib vs rituximab plus idelalisib (IdR) or bendamustine (BR) in previously treated chronic lymphocytic leukemia (CLL): ASCEND final results. J Clin Oncol. 2020; 38 (15_suppl): 8000. DOI: 10.1016/j.clml.2019.07.217Ghia P., Pluta A., Wach M., Lysak D., Kozak T., Simkovic M. et al. Acalabrutinib vs rituximab plus idelalisib (IdR) or bendamustine (BR) in previously treated chronic lymphocytic leukemia (CLL): ASCEND final results. J Clin Oncol. 2020; 38 (15_suppl): 8000. DOI: 10.1016/j.clml.2019.07.217Miao Y., Xu W., Li J. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2021; 17 (9): 1023–30. DOI: 10.1080/17425255.2021.195585526 Miao Y., Xu W., Li J. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2021; 17 (9): 1023–30. DOI: 10.1080/17425255.2021.1955855Devos T., Havelange V., Theunissen K., Meers S., Benghiat F. S., Gadisseur A., et al. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry. Ann Hematol. 2021; 100 (7): 1723–32. DOI: 10.1007/s00277-021-04507-xDevos T., Havelange V., Theunissen K., Meers S., Benghiat F. S., Gadisseur A., et al. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry. Ann Hematol. 2021; 100 (7): 1723–32. DOI: 10.1007/s00277-021-04507-xKantarjian H., Shah N. P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362 (24): 2260–70. DOI: 10.1056/NEJMoa1002315Kantarjian H., Shah N. P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362 (24): 2260–70. DOI: 10.1056/NEJMoa1002315Zackova D., Klamova H., Belohlavkova P., Stejskal L., Necasova T., Semerad L., et al. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. Leuk Lymphoma. 2021; 62 (1): 194–202. DOI: 10.1080/10428194.2020.1827242Zackova D., Klamova H., Belohlavkova P., Stejskal L., Necasova T., Semerad L., et al. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. Leuk Lymphoma. 2021; 62 (1): 194–202. DOI: 10.1080/10428194.2020.1827242Erçalışkan A., Avcı F. Z., Eşkazan A. E. Successful management of ibrutinib-induced thrombocytopenia with eltrombopag in a patient with waldenström macroglobulinemia. Turk J Haematol. 2022; 39 (4): 275–6. DOI: 10.4274/tjh.galenos.2022.2022.0397Erçalışkan A., Avcı F. Z., Eşkazan A. E. Successful management of ibrutinib-induced thrombocytopenia with eltrombopag in a patient with waldenström macroglobulinemia. Turk J Haematol. 2022; 39 (4): 275–6. DOI: 10.4274/tjh.galenos.2022.2022.0397McKean M., Oba J., Ma J., Roth K. G., Wang W. L., Macedo M. P., et al. Tyrosine kinase inhibitor and immune checkpoint inhibitor responses in KIT-mutant metastatic melanoma. J Invest Dermatol. 2019; 139 (3): 728–31. DOI: 10.1016/j.jid.2018.10.009McKean M., Oba J., Ma J., Roth K. G., Wang W. L., Macedo M. P., et al. Tyrosine kinase inhibitor and immune checkpoint inhibitor responses in KIT-mutant metastatic melanoma. J Invest Dermatol. 2019; 139 (3): 728–31. DOI: 10.1016/j.jid.2018.10.009Wu J., Zhang M., Liu D., Sun J. Successful management of a patient with ibrutinib-induced neutropenia using filgrastim. Ann Hematol. 2020; 99 (4): 917–8.Wu J., Zhang M., Liu D., Sun J. Successful management of a patient with ibrutinib-induced neutropenia using filgrastim. Ann Hematol. 2020; 99 (4): 917–8.Petrucci M. T., Giraldo P., Corradini P., Teixeira A., Dimopoulos M. A., Blau I. W., et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol. 2013; 160 (5): 649–59. DOI: 10.1111/bjh.12198Petrucci M. T., Giraldo P., Corradini P., Teixeira A., Dimopoulos M. A., Blau I. W., et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol. 2013; 160 (5): 649–59. DOI: 10.1111/bjh.12198Lee S. R., Choi H., Lee B. H., Kang K. W., Yu E. S., Kim D. S., et al. Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. Korean J Intern Med. 2019; 34 (6): 1333–46. DOI: 10.3904/kjim.2018.144Lee S. R., Choi H., Lee B. H., Kang K. W., Yu E. S., Kim D. S., et al. Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. Korean J Intern Med. 2019; 34 (6): 1333–46. DOI: 10.3904/kjim.2018.144Yao R., Hu X., Zhou S., Zhang Q., Huang H., Sun N., et al. Onceweekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China. Medicine (Baltimore). 2019; 98 (39): e17147. DOI: 10.1097/MD.0000000000017147Yao R., Hu X., Zhou S., Zhang Q., Huang H., Sun N., et al. Onceweekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China. Medicine (Baltimore). 2019; 98 (39): e17147. DOI: 10.1097/MD.0000000000017147Stork M., Sevcikova S., Brozova L., Spicka I., Maisnar V., Minarik J., et al. Bortezomib retreatment is effective in relapsed multiple myeloma patients — real-life clinical practice data. Neoplasma. 2020; 67 (1): 178–84. DOI: 10.4149/neo_2019_190430N383Stork M., Sevcikova S., Brozova L., Spicka I., Maisnar V., Minarik J., et al. Bortezomib retreatment is effective in relapsed multiple myeloma patients — real-life clinical practice data. Neoplasma. 2020; 67 (1): 178–84. DOI: 10.4149/neo_2019_190430N383Dimopoulos M. A., Špička I., Quach H., Oriol A., Hájek R., Garg M., et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 Trial. J Clin Oncol. 2020; 38 (34): 4030–41. DOI: 10.1200/JCO.20.02060Dimopoulos M. A., Špička I., Quach H., Oriol A., Hájek R., Garg M., et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 Trial. J Clin Oncol. 2020; 38 (34): 4030–41. DOI: 10.1200/JCO.20.02060Facon T., Venner C. P., Bahlis N. J., Offner F., White D. J., Karlin L., et al. Oral ixazomib, lenalidomide, and dexamethasone for transplantineligible patients with newly diagnosed multiple myeloma. Blood. 2021; 137 (26): 3616–28. DOI: 10.1182/blood.2020008787Facon T., Venner C. P., Bahlis N. J., Offner F., White D. J., Karlin L., et al. Oral ixazomib, lenalidomide, and dexamethasone for transplantineligible patients with newly diagnosed multiple myeloma. Blood. 2021; 137 (26): 3616–28. DOI: 10.1182/blood.2020008787Ghia P., Pluta A., Wach M., Lysak D., Kozak T., Simkovic M., et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020; 38 (25): 2849–61. DOI: 10.1200/JCO.19.03355Ghia P., Pluta A., Wach M., Lysak D., Kozak T., Simkovic M., et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020; 38 (25): 2849–61. DOI: 10.1200/JCO.19.03355Byrd J. C., Wierda W. G., Schuh A., Devereux S., Chaves J. M., Brown J. R., et al. Acalabrutinib monotherapy in patients with relapsed / refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020; 135 (15): 1204–13. DOI: 10.1182/blood.2018884940Byrd J. C., Wierda W. G., Schuh A., Devereux S., Chaves J. M., Brown J. R., et al. Acalabrutinib monotherapy in patients with relapsed / refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020; 135 (15): 1204–13. DOI: 10.1182/blood.2018884940Tam C. S., Trotman J., Opat S., Burger J. A., Cull G., Gottlieb D., et al. Safety and activity of the investigational Bruton tyrosine kinase inhibitor orelabrutinib (ICP-022) in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Haematol. 2020; 7 (5): e371–82.Tam C. S., Trotman J., Opat S., Burger J. A., Cull G., Gottlieb D., et al. Safety and activity of the investigational Bruton tyrosine kinase inhibitor orelabrutinib (ICP-022) in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Haematol. 2020; 7 (5): e371–82.Deveraux Q. L., Schendel S. L., Reed J. C. Debio-1143 (AT-406), a small molecule antagonist of inhibitor of apoptosis proteins (IAPs), exhibits cancer-specific activity via dual mechanisms. Oncotarget. 2014; 5 (3): 561–73. PMID: 24515228.Deveraux Q. L., Schendel S. L., Reed J. C. Debio-1143 (AT-406), a small molecule antagonist of inhibitor of apoptosis proteins (IAPs), exhibits cancer-specific activity via dual mechanisms. Oncotarget. 2014; 5 (3): 561–73. PMID: 24515228.Ramadass V., Vaiyapuri T., Tergaonkar V. Small molecule NF-κB pathway inhibitors in clinic. Int J Mol Sci. 2020; 21 (14): 5164. DOI: 10.3390/ijms21145164Ramadass V., Vaiyapuri T., Tergaonkar V. Small molecule NF-κB pathway inhibitors in clinic. Int J Mol Sci. 2020; 21 (14): 5164. DOI: 10.3390/ijms21145164Guan C., Zhou X., Li H., Ma X., Zhuang J. NF-κB inhibitors gifted by nature: The anticancer promise of polyphenol compounds. Biomed Pharmacother. 2022; 156: 113951. DOI: 10.1016/j.biopha.2022.113951Guan C., Zhou X., Li H., Ma X., Zhuang J. NF-κB inhibitors gifted by nature: The anticancer promise of polyphenol compounds. Biomed Pharmacother. 2022; 156: 113951. DOI: 10.1016/j.biopha.2022.113951Umezawa K., Breborowicz A., Gantsev S. Anticancer activity of novel NF-kappa B inhibitor DHMEQ by intraperitoneal administration. Oncol Res. 2020; 28 (5): 541–50. DOI: 10.3727/096504020X15929100013698Umezawa K., Breborowicz A., Gantsev S. Anticancer activity of novel NF-kappa B inhibitor DHMEQ by intraperitoneal administration. Oncol Res. 2020; 28 (5): 541–50. DOI: 10.3727/096504020X15929100013698Kojima K., Takahashi T., Taira N. Phase I clinical trial of intravenous administration of the NF-kappaB inhibitor dehydroxymethylepoxy-quinomicin in patients with relapsed/refractory B-cell lymphoma. Cancer Sci. 2018; 109 (5): 1799–805. DOI: 10.1111/cas.13574Kojima K., Takahashi T., Taira N. Phase I clinical trial of intravenous administration of the NF-kappaB inhibitor dehydroxymethylepoxy-quinomicin in patients with relapsed/refractory B-cell lymphoma. Cancer Sci. 2018; 109 (5): 1799–805. DOI: 10.1111/cas.13574Ishikawa M., Yoshida K., Yamamoto Y., Nomura M., Takenaga F. Dehydroxymethylepoxyquinomicin (DHMEQ), a potent NF-kappaB inhibitor, enhances TRAIL-mediated apoptosis in renal cancer cells. Oncol Rep. 2005; 14 (5): 1201–5.Ishikawa M., Yoshida K., Yamamoto Y., Nomura M., Takenaga F. Dehydroxymethylepoxyquinomicin (DHMEQ), a potent NF-kappaB inhibitor, enhances TRAIL-mediated apoptosis in renal cancer cells. Oncol Rep. 2005; 14 (5): 1201–5.Morita S., Shinoda K., Yoshida T., Shimoda M., Kanno Y., Mizuno R., et al. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model. BMC Pharmacol Toxicol. 2020; 21 (1): 60. DOI: 10.1186/s40360-020-00432-3Morita S., Shinoda K., Yoshida T., Shimoda M., Kanno Y., Mizuno R., et al. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model. BMC Pharmacol Toxicol. 2020; 21 (1): 60. DOI: 10.1186/s40360-020-00432-3Ando Y., Keino H., Kudo A., Hirakata A., Okada A. A., Umezawa K. Anti-inflammatory effect of Dehydroxymethylepoxyquinomicin, a Nuclear factor-κB inhibitor, on endotoxin-induced uveitis in rats in vivo and in vitro. Ocul Immunol Infl amm. 2020; 28 (2): 240–8. DOI: 10.1080/09273948.2019.1568502Ando Y., Keino H., Kudo A., Hirakata A., Okada A. A., Umezawa K. Anti-inflammatory effect of Dehydroxymethylepoxyquinomicin, a Nuclear factor-κB inhibitor, on endotoxin-induced uveitis in rats in vivo and in vitro. Ocul Immunol Infl amm. 2020; 28 (2): 240–8. DOI: 10.1080/09273948.2019.1568502Ma J., Zhang Y., Sugai T., Kubota T., Keino H., El-Salhy M., et al. Inhibition of cellular and animal infl ammatory disease models by NF-κB inhibitor DHMEQ. Cells. 2021; 10 (9): 2271. DOI: 10.3390/cells10092271Ma J., Zhang Y., Sugai T., Kubota T., Keino H., El-Salhy M., et al. Inhibition of cellular and animal infl ammatory disease models by NF-κB inhibitor DHMEQ. Cells. 2021; 10 (9): 2271. DOI: 10.3390/cells10092271

The authors declare that there are no conflicts of interest present.